Clinical trial
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia…
NCT00264160 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00264160 |
|---|---|
| Title | Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy |
| Official title | Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic |
| Intervention type | Drug |
| Interventions | AMN107 |
| Enrollment | 36 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Aug 1, 2009 |
| First posted | Dec 12, 2005 |
| Last update posted | Mar 6, 2017 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: